公开(公告)号：EP2770993A2

公开(公告)日：2014-09-03

申请号：EP12783789.6

申请日：2012-10-26

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  Provid Pharmaceuticals Inc.

发明人： WAUGH, David ,  SELF, Christopher ,  ZHANG, Guangtao ,  POMMIER, Yves ,  SHOEMAKER, Robert H. ,  CURRENS, Michael ,  CARDELLINA, John ,  JOBSON, Andrew ,  LOUNTOS, George ,  SCUDIERO, Dominic A.

IPC分类号： A61K31/404 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/4709 ,  C07D209/04 ,  A61P31/14

CPC分类号： A61K31/4184 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/4709 ,  A61K45/06 ,  C07D209/42 ,  C07D401/12 ,  C07D403/12 ,  C12N9/96

摘要： A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G
1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.

摘要翻译： 一种治疗患者中丙型肝炎病毒感染的方法，包括向有需要的患者提供治疗有效量的式（I）化合物或其药学上可接受的盐，其中：G1是 式或其中n为0,1,2,3或4，并且Het为含有1至4个独立地选自N，O和S的杂原子的5-或6-元杂芳基，该Het任选被取代。